Arovella Therapeutics Ltd E4NA.BE
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
E4NA.BE Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Arovella Therapeutics Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Arovella Therapeutics Ltd. Stock Analysis E4NA.BE
Germany Health Care Micro Cap Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. The firm is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Its lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. The company is also expanding into solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. The company focuses on integrating IL-12-TM technology into its solid tumor programs.
Arovella Therapeutics Ltd (E4NA.BE) Chart
Financial Metrics & Statements of Arovella Therapeutics Ltd (E4NA.BE)
FAQ's for Arovella Therapeutics Ltd (E4NA.BE)
- As of September 2026, Arovella Therapeutics Ltd E4NA.BE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Arovella Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Arovella Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Arovella Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Arovella Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Arovella Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Arovella Therapeutics Ltd (E4NA.BE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
